A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Moderately to Severely Active Crohn's Disease
Latest Information Update: 15 Jun 2025
At a glance
- Drugs Tulisokibart (Primary) ; Tulisokibart (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co; Prometheus Biosciences
Most Recent Events
- 10 Mar 2025 Planned End Date changed from 8 Oct 2032 to 12 Nov 2029.
- 10 Mar 2025 Planned primary completion date changed from 11 Sep 2029 to 30 Oct 2028.
- 25 Jul 2024 Planned End Date changed from 11 Sep 2029 to 8 Oct 2032.